PODD Insulet Corporation
Company Analysis
Latest News
Insulet Hit With Class Action, Alleging Omnipod Insulin Under-Delivery
Pomerantz LLP filed a class action lawsuit against Insulet Corporation on July 3, 2026. The complaint alleges that Insulet and its officers violated federal...
🟢 PODD is trading 4.8% up today as it extends a sharp intraday rebound
PODD is trading at $167.53 (+4.84%) in after-hours trading, extending gains from a strong regular-session rebound on July 1. • The move appears to be driven...
🟢 PODD extends move to 5.2% up
PODD is trading at $160.21, up 5.2% versus the comparison close of $152.25 during regular trading. This is a price-movement alert; no separate company-specific...
🟢 PODD is trading 4.2% up today as analyst price targets signal 57% upside potential
PODD is trading 4.2% up at $158.65 as investors focus on the long-term growth narrative following a reset in analyst price targets. • New coverage from 23...
Insulet Surges 16% in Three Days on Deutsche Bank's Bullish Call — But Can a Beaten-Down Diabetes Stock Really Close a $29 Gap to Its Target?
Shares of Insulet Corporation vaulted to $161.41 in after-hours trading Wednesday, capping a 16% three-day rally from last Monday's close of $138.97 — a level...
🟢 PODD is trading 8.4% up today, extending a rebound fueled by a bullish Deutsche Bank initiation
PODD is trading at $161.41 (8.4% up) in after-hours trading, extending a sharp rebound from last week’s selloff. • The move follows bullish sentiment sparked...
🟢 PODD Surges 4.8% as Deutsche Bank Initiates 'Buy' Rating
Insulet Corporation (PODD) shares are trading at $145.57 (+4.8%) after Deutsche Bank initiated coverage with a Buy rating and a $190.00 price target today. •...
🔴 Insulet Corporation is trading 4.5% down today with no clear catalyst
Insulet Corporation is trading 4.5% down at $139.27 today amid a lack of fresh headlines, suggesting the move is driven by normal volatility and positioning...
🟢 Insulet Corporation is trading 4.5% up today as it bounces from a sharp regular-session drop
Insulet Corporation is trading at $157.49 (+4.50%) in after-hours trading, rebounding from a sharp decline during the regular session on June 10. • No...
🔴 Insulet Corporation is trading 5.1% down today on profit-taking after yesterday's Omnipod 5 rally
Insulet Corporation is trading at $151.53 (5.1% down) as investors lock in gains following a significant surge driven by Omnipod 5 optimism. • The pullback...
🔴 Insulet Corporation is trading 4.1% down today on profit-taking after its Omnipod 5-driven rally
Insulet Corporation is trading at $153.00 (down 4.1%), giving back part of its sharp June 9, 2026, jump that followed optimism around Omnipod 5 software...
🟢 Insulet Corporation is trading 5.3% up today on Omnipod 5 upgrades and expanded CGM compatibility
Insulet Corporation is trading 5.3% up today at $159.56 as investors react to the U.S. rollout of Omnipod 5 algorithm upgrades and expanded CGM...
🟢 Insulet Corporation is trading 4.1% up today as it rebounds from recent weakness
Insulet Corporation is trading 4.1% up at $157.66 as the stock rebounds from recent weakness and outperforms its prior close of $151.51. • Current gains...
Insulet Omnipod 6 boosts glucose control in pivotal STRIVE trial
Insulet announced clinical results for its next-generation tubeless insulin delivery systems at the American Diabetes Association's 86th Scientific...
🟢 Insulet Corporation is trading 5.2% up today on Omnipod 5 enhancements and Abbott sensor integration
Insulet Corporation is trading 5.2% up at $153.99 following the U.S. rollout of significant enhancements to its Omnipod 5 automated insulin delivery system. •...
🟢 Insulet Corporation is trading 4.5% up today on Omnipod 5 upgrade and Abbott sensor integration
Insulet Corporation is trading 4.5% up today at $152.93 after investors reacted positively to the U.S. rollout of enhancements for the Omnipod 5 insulin...
🟢 Insulet Corporation is trading 4.2% up today on the U.S. rollout of Omnipod 5 upgrades and Libre 3 compatibility
Insulet Corporation is trading 4.21% up now at $149.34 as the company begins the U.S. rollout of major upgrades to its Omnipod 5 Automated Insulin Delivery...
Insulet Upgrades Omnipod 5, Adding Abbott FreeStyle Libre 3 Compatibility
Insulet Corporation has initiated the U.S. rollout of significant enhancements to its Omnipod 5 Automated Insulin Delivery (AID) System. The FDA cleared the...
🔴 Insulet Corporation is trading 4.1% down today following a voluntary device correction for its Omnipod pods
Insulet Corporation is trading 4.1% down today at $142.00 after the company initiated a voluntary medical device correction for certain lots of its Omnipod...
Insulet loses $59M trade secret award, filed lawsuit too late
A U.S. appeals court overturned a $59.4 million verdict for medical device maker Insulet against South Korean competitor EOFlow. The U.S. Court of Appeals for...